Can stem cell-based platforms become successful treatments for neurodegenerative diseases?

•  What are the commonalities driving GCT success in neurodegenerative disease and non-neurologic disease, what are the key differences?
• Overcoming treatment administration challenges
• GCT impact on degenerative stage of disease
• How difficult will it be to titrate the size of the cell therapy effect in different neurological disorders and for different patients?
• Demonstrating clinical value to patients and payers
• Revised clinical trial models to address issues and concerns specific to GCT